Communiqués Aquestive Therapeutics, Inc.

Actions

AQST

US03843E1047

Produits pharmaceutiques

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
4,780 ^USD	+0,42 %		+5,05 %	-26,01 %

29/09	Aquestive Therapeutics, Inc. annonce la nomination de Richard J. Daly au conseil d’administration, avec prise d’effet le 14 octobre 2026	CI
17/09	Aquestive Therapeutics dépose à nouveau sa demande d'autorisation de mise sur le marché auprès de la FDA pour le film sublingual Anaphylm (dibutépinéphrine)	CI

Communiqués

29/09	Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly	GL
17/09	Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film	GL
01/09	Aquestive Therapeutics to Participate in Upcoming September Investor Conferences	GL
11/08	Aquestive Therapeutics: Q2 Earnings Snapshot	AQ
11/08	Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
11/08	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film	AQ
10/08	Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film	GL
29/07	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET	GL
29/07	Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8:00 a.m. ET	AQ
07/07	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism	GL
13/05	Aquestive Therapeutics: Q1 Earnings Snapshot	AQ
13/05	Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	GL
12/05	Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree	GL
06/05	Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET	GL
04/05	AQST Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
03/05	AQST Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
02/05	AQST 72 HOUR DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
29/04	AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
28/04	AQST INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
25/04	AQST INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
23/04	AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
20/04	AQST UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
18/04	AQST CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics (AQST) Investors of Securities Class Action Deadline on May 4, 2026	NE
14/04	AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT Bernstein Liebhard LLP Reminds Aquestive Therapeutics, Inc. Investors of Upcoming Deadline	NE
13/04	Faruqi & Faruqi, LLP Highlights Class Action Against Aquestive (AQST) and Upcoming Lead Plaintiff Deadline of May 4, 2026	NE